Logotype for Hofseth BioCare

Hofseth BioCare (HBC) investor relations material

Hofseth BioCare Q2 2025 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Hofseth BioCare
Q2 2025 earnings summary22 Aug, 2025

Executive summary

  • Q2 2025 was a transitional quarter with lower revenues but significant gross margin expansion to 46% from 34% year-over-year, reflecting a strategic shift toward higher-value human and pet health products.

  • Operational EBITDA turned positive at NOK 1.3 million, up from NOK -2.5 million in Q2 2024, despite one-time restructuring charges.

  • Human B2B segment saw 180% revenue growth year-over-year, driven by strong demand in Europe, China, and Southeast Asia, and a major global product launch.

  • Consumer and Pet Health (B2C) revenues were flat, but net profitability improved by 10%, with growth expected to accelerate in H2 as supply constraints ease.

  • R&D pipeline advanced with key studies in bone, joint, cognitive, and oncology health, and new publications and awards for flagship products.

Financial highlights

  • Q2 2025 operating revenue was NOK 68.4 million, down from NOK 80.4 million in Q2 2024; H1 2025 revenue was NOK 129.3 million, nearly flat year-over-year.

  • Gross margin rose to 46% from 34% in Q2 2024, reflecting a shift away from commodity sales.

  • EBITDA was NOK -5.4 million, but adjusted Operational EBITDA was NOK 1.3 million, excluding NOK 3.0 million in restructuring and other non-recurring costs.

  • EBIT for Q2 was NOK -14.9 million (Q2 2024: NOK -11.6 million); net financial items worsened to NOK -10.1 million due to new loans.

  • Cash flow from operations was negative NOK 34.2 million, mainly due to increased inventory and changes in receivables/payables.

  • Cash and cash equivalents at quarter-end were NOK 68.0 million, with total liquidity (including credit lines) at NOK 76.5 million.

  • Equity ratio at group level dropped to 0.1% (Q2 2024: 35.7%), but parent company Covenant Equity Ratio remained compliant at 29.4%.

Outlook and guidance

  • H2 2025 is expected to deliver over 20% revenue growth in B2C, with supply chain constraints anticipated to be fully resolved by Q4.

  • Softgels business forecasted to grow over 50% in the next 12 months as new customer listings and supply improvements take effect.

  • Continued focus on margin expansion, operational discipline, and science-led innovation to drive long-term value creation.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Hofseth BioCare earnings date

Logotype for Hofseth BioCare
Q3 20257 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Hofseth BioCare earnings date

Logotype for Hofseth BioCare
Q3 20257 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Hofseth BioCare ASA is a biotechnology company that focuses on the production of high-value ingredients derived from fish. The company develops and commercializes sustainable biomarine products for human and pet health. Its product portfolio includes bioactive peptides, oils, calcium, and proteins, which are used in a variety of industries, including dietary supplements, clinical nutrition, and functional foods. Hofseth BioCare emphasizes utilizing fresh raw materials and applying a gentle enzymatic hydrolysis process to retain the nutritional properties of the fish. The company is headquartered in Ålesund, Norway, and its shares are listed on the Oslo Stock Exchange.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage